View Item 

Show simple item record

Dissecting the Heterogeneity of Skin Gene Expression Patterns in Systemic Sclerosis
dc.contributor.authorAssassi, Shervinen_US
dc.contributor.authorSwindell, William R.en_US
dc.contributor.authorWu, Minghuaen_US
dc.contributor.authorTan, Filemon D.en_US
dc.contributor.authorKhanna, Dineshen_US
dc.contributor.authorFurst, Daniel E.en_US
dc.contributor.authorTashkin, Donald P.en_US
dc.contributor.authorJahan‐tigh, Richard R.en_US
dc.contributor.authorMayes, Maureen D.en_US
dc.contributor.authorGudjonsson, Johann E.en_US
dc.contributor.authorChang, Jeffrey T.en_US
dc.date.accessioned2015-11-12T21:04:36Z
dc.date.available2017-01-03T16:21:17Zen
dc.date.issued2015-11en_US
dc.identifier.citationAssassi, Shervin; Swindell, William R.; Wu, Minghua; Tan, Filemon D.; Khanna, Dinesh; Furst, Daniel E.; Tashkin, Donald P.; Jahan‐tigh, Richard R. ; Mayes, Maureen D.; Gudjonsson, Johann E.; Chang, Jeffrey T. (2015). "Dissecting the Heterogeneity of Skin Gene Expression Patterns in Systemic Sclerosis." Arthritis & Rheumatology 67(11): 3016-3026.en_US
dc.identifier.issn2326-5191en_US
dc.identifier.issn2326-5205en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/115989
dc.publisherWiley Periodicals, Inc.en_US
dc.titleDissecting the Heterogeneity of Skin Gene Expression Patterns in Systemic Sclerosisen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelRheumatologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/115989/1/art39289.pdf
dc.identifier.doi10.1002/art.39289en_US
dc.identifier.sourceArthritis & Rheumatologyen_US
dc.identifier.citedreferenceSwindell WR, Stuart PE, Sarkar MK, Voorhees JJ, Elder JT, Johnston A, et al. Cellular dissection of psoriasis for transcriptome analyses and the post‐GWAS era. BMC Med Genomics 2014; 7: 27.en_US
dc.identifier.citedreferenceAssassi S, Sharif R, Lasky RE, McNearney TA, Estrada YM, Draeger HT, et al. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther 2010; 12: R166.en_US
dc.identifier.citedreferenceKhanna D, Saggar R, Mayes MD, Abtin F, Clements PJ, Maranian P, et al. A one‐year, phase I/IIa, open‐label pilot trial of imatinib mesylate in the treatment of systemic sclerosis–associated active interstitial lung disease. Arthritis Rheum 2011; 63: 3540 – 6.en_US
dc.identifier.citedreferenceVan den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737 – 47.en_US
dc.identifier.citedreferenceLeroy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988; 15: 202 – 5.en_US
dc.identifier.citedreferenceClements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281 – 5.en_US
dc.identifier.citedreferenceTusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001; 98: 5116 – 21.en_US
dc.identifier.citedreferenceKenny PA, Enver T, Ashworth A. Receptor and secreted targets of Wnt‐1/β‐catenin signalling in mouse mammary epithelial cells. BMC Cancer 2005; 5: 3.en_US
dc.identifier.citedreferenceSwindell WR, Johnston A, Voorhees JJ, Elder JT, Gudjonsson JE. Dissecting the psoriasis transcriptome: inflammatory‐ and cytokine‐driven gene expression in lesions from 163 patients. BMC Genomics 2013; 14: 527.en_US
dc.identifier.citedreferencePalmer C, Diehn M, Alizadeh AA, Brown PO. Cell‐type specific gene expression profiles of leukocytes in human peripheral blood. BMC Genomics 2006; 7: 115.en_US
dc.identifier.citedreferenceHaider AS, Lowes MA, Suarez‐Farinas M, Zaba LC, Cardinale I, Blumenberg M, et al. Cellular genomic maps help dissect pathology in human skin disease. J Invest Dermatol 2008; 128: 606 – 15.en_US
dc.identifier.citedreferenceSwindell WR, Johnston A, Xing X, Voorhees JJ, Elder JT, Gudjonsson JE. Modulation of epidermal transcription circuits in psoriasis: new links between inflammation and hyperproliferation. PLoS One 2013; 8: e79253.en_US
dc.identifier.citedreferenceTabata H, Hara N, Otsuka S, Yamakage A, Yamazaki S, Koibuchi N. Correlation between diffuse pigmentation and keratinocyte‐derived endothelin‐1 in systemic sclerosis. Int J Dermatol 2000; 39: 899 – 902.en_US
dc.identifier.citedreferenceRudnicka L, Varga J, Christiano AM, Iozzo RV, Jimenez SA, Uitto J. Elevated expression of type VII collagen in the skin of patients with systemic sclerosis: regulation by transforming growth factor‐β. J Clin Invest 1994; 93: 1709 – 15.en_US
dc.identifier.citedreferenceDistler O, Pap T, Kowal‐Bielecka O, Meyringer R, Guiducci S, Landthaler M, et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet‐derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum 2001; 44: 2665 – 78.en_US
dc.identifier.citedreferenceDavies CA, Jeziorska M, Freemont AJ, Herrick AL. The differential expression of VEGF, VEGFR‐2, and GLUT‐1 proteins in disease subtypes of systemic sclerosis. Hum Pathol 2006; 37: 190 – 7.en_US
dc.identifier.citedreferenceDistler JH, Jungel A, Kowal‐Bielecka O, Michel BA, Gay RE, Sprott H, et al. Expression of interleukin‐21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum 2005; 52: 856 – 64.en_US
dc.identifier.citedreferenceAden N, Shiwen X, Aden D, Black C, Nuttall A, Denton CP, et al. Proteomic analysis of scleroderma lesional skin reveals activated wound healing phenotype of epidermal cell layer. Rheumatology (Oxford) 2008; 47: 1754 – 60.en_US
dc.identifier.citedreferenceAden N, Nuttall A, Shiwen X, de Winter P, Leask A, Black CM, et al. Epithelial cells promote fibroblast activation via IL‐1α in systemic sclerosis. J Invest Dermatol 2010; 130: 2191 – 200.en_US
dc.identifier.citedreferenceHardy MH. The secret life of the hair follicle. Trends Genet 1992; 8: 55 – 61.en_US
dc.identifier.citedreferenceLo CC, Prowse DM, Watt FM. Transient activation of β‐catenin signalling in adult mouse epidermis is sufficient to induce new hair follicles but continuous activation is required to maintain hair follicle tumours. Development 2004; 131: 1787 – 99.en_US
dc.identifier.citedreferenceLowry WE, Blanpain C, Nowak JA, Guasch G, Lewis L, Fuchs E. Defining the impact of β‐catenin/Tcf transactivation on epithelial stem cells. Genes Dev 2005; 19: 1596 – 611.en_US
dc.identifier.citedreferenceVan Mater D, Kolligs FT, Dlugosz AA, Fearon ER. Transient activation of β‐catenin signaling in cutaneous keratinocytes is sufficient to trigger the active growth phase of the hair cycle in mice. Genes Dev 2003; 17: 1219 – 24.en_US
dc.identifier.citedreferenceWei J, Fang F, Lam AP, Sargent JL, Hamburg E, Hinchcliff ME, et al. Wnt/β‐catenin signaling is hyperactivated in systemic sclerosis and induces Smad‐dependent fibrotic responses in mesenchymal cells. Arthritis Rheum 2012; 64: 2734 – 45.en_US
dc.identifier.citedreferenceElhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta‐analysis of cohort studies. Rheumatology (Oxford) 2011; 51: 1017 – 26.en_US
dc.identifier.citedreferenceBullinger L, Dohner K, Bair E, Frohling S, Schlenk RF, Tibshirani R, et al. Use of gene‐expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004; 350: 1605 – 16.en_US
dc.identifier.citedreferenceBaechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon‐inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003; 100: 2610 – 5.en_US
dc.identifier.citedreferenceBeer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, et al. Gene‐expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002; 8: 816 – 24.en_US
dc.identifier.citedreferenceVan Baarsen LG, Vosslamber S, Tijssen M, Baggen JM, van der Voort LF, Killestein J, et al. Pharmacogenomics of interferon‐β therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One 2008; 3: e1927.en_US
dc.identifier.citedreferenceKandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497: 67 – 73.en_US
dc.identifier.citedreferenceGardner H, Shearstone JR, Bandaru R, Crowell T, Lynes M, Trojanowska M, et al. Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum 2006; 54: 1961 – 73.en_US
dc.identifier.citedreferenceHsu E, Shi H, Jordan RM, Lyons‐Weiler J, Pilewski JM, Feghali‐Bostwick CA. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum 2011; 63: 783 – 94.en_US
dc.identifier.citedreferenceMilano A, Pendergrass SA, Sargent JL, George LK, McCalmont TH, Connolly MK, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One 2008; 3: e2696.en_US
dc.identifier.citedreferenceWhitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, et al. Systemic and cell type‐specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 2003; 100: 12319 – 24.en_US
dc.identifier.citedreferenceAssassi S, Mayes MD, Arnett FC, Gourh P, Agarwal SK, McNearney TA, et al. Systemic sclerosis and lupus: points in an interferon‐mediated continuum. Arthritis Rheum 2010; 62: 589 – 98.en_US
dc.identifier.citedreferenceChristmann RB, Hayes E, Pendergrass S, Padilla C, Farina G, Affandi AJ, et al. Interferon and alternative activation of monocyte/macrophages in systemic sclerosis–associated pulmonary arterial hypertension. Arthritis Rheum 2011; 63: 1718 – 28.en_US
dc.identifier.citedreferenceHiggs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011; 70: 2029 – 36.en_US
dc.identifier.citedreferenceStreicher K, Morehouse CA, Groves CJ, Rajan B, Pilataxi F, Lehmann KP, et al. The plasma cell signature in autoimmune disease. Arthritis Rheumatol 2014; 66: 173 – 84.en_US
dc.identifier.citedreferenceTan FK, Zhou X, Mayes MD, Gourh P, Guo X, Marcum C, et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 2006; 45: 694 – 702.en_US
dc.identifier.citedreferenceHinchcliff M, Huang CC, Wood TA, Mahoney JM, Martyanov V, Bhattacharyya S, et al. Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis. J Invest Dermatol 2013; 133: 1979 – 89.en_US
dc.identifier.citedreferencePendergrass SA, Lemaire R, Francis IP, Mahoney JM, Lafyatis R, Whitfield ML. Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies. J Invest Dermatol 2012; 132: 1363 – 73.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
art39289.pdf
Size:
641.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.